Roche used ECTRIMS 2025 to consolidate its multiple sclerosis franchise on two fronts: durability and diversification. New data show the subcutaneous formulation of Ocrevus sustained a consistent benefit–risk profile over two years, mirroring the intravenous version’s impact on relapses, MRI activity, and disability. Late-breaking results from ORATORIO-Hand in an expanded primary progressive MS population, including older adults and patients with more advanced disability, demonstrated a 30% reduction in the risk of 12-week composite confirmed disability progression versus placebo over a median 2.75 years, rising to 55% in participants with MRI lesion activity at baseline. Additional datasets address key edge cases that often stall treatment decisions: infants potentially exposed to Ocrevus in utero or via breastfeeding mounted robust responses to routine vaccinations at one year, and pediatric studies in relapsing–remitting MS position Ocrelizumab against fingolimod in a high-efficacy head-to-head.
The strategic question is whether Roche can turn breadth into dominance as MS care shifts from relapse control to sustained progression management. Ocrevus remains the only approved therapy for PPMS, and evidence of benefit in more advanced, heterogeneous patients could expand its real-world reach and underpin payer confidence for older and higher-EDSS segments where functional preservation, especially of upper limbs, is central to independence. The subcutaneous, twice-yearly dosing is a commercial lever, offering site-of-care flexibility that pressures infusion-center economics and counterbalances the convenience narrative of monthly anti-CD20 competitors. For Medical Affairs, pregnancy and lactation data reduce a critical barrier to prescriber comfort, opening the door to clearer guidance on vaccination schedules and infant monitoring that can be translated into practice without sacrificing immunoprotection.
Roche is also preparing a potential pivot within its own portfolio. Two-year open-label extension results for fenebrutinib, a CNS-penetrant, reversible BTK inhibitor, showed near-complete suppression of disease activity at 96 weeks with a low annualized relapse rate, no observed disability progression by EDSS, zero new T1 gadolinium-enhancing lesions, and neurofilament light levels normalized to a healthy range and maintained through year two. Phase III readouts are imminent, including FENTREPID in PPMS, notably designed against Ocrevus. That head-to-head stance is unusual and deliberate: if an oral BTK can match or exceed Ocrevus on progression metrics, Roche trades cannibalization risk for class leadership at a moment when competitors’ BTK programs have been weighed down by safety and efficacy uncertainties.
The timing matters. Payers are sharpening definitions of value around slowing disability, not just annualized relapse rates, and are increasingly receptive to biomarker-supported narratives that predict long-term cost offsets. Regulators are signaling openness to special-population evidence packages that address unanswered clinical questions in pregnancy, lactation, and pediatrics. HCPs are recalibrating treatment algorithms toward early, high-efficacy choices that minimize progression, a shift that advantages mechanisms targeting B cells and, potentially, microglial activation. For competitors, the message is stark: convenience alone will not suffice if progression data are thin, and trial designs must increasingly capture functional outcomes meaningful to daily living.
Near term, watch for how quickly the subcutaneous format drives site-of-care migration and whether pediatric and perinatal data translate into label and guideline updates that unlock new segments. The decisive catalyst will be the fenebrutinib pivotal data—particularly in PPMS—where an oral, progression-focused agent could reset standards. The industry-level question is whether MS’s next frontline will be defined by anti-CD20 durability or by BTK-driven, neuroinflammation-modulating convenience, and which evidence package will persuade payers to underwrite earlier, broader use.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
